Skip to main content
SpringerLink
Log in

Adjuvant chemotherapy of breast cancer: Hope — Reality — Hazard?

  • Übersichten
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

According to a NIH Consensus-Development Statement, adjuvant polychemotherapy following mastectomy is considered beneficial to premenopausal patients with positive axillary nodes. Nevertheless, the role of adjuvant chemotherapy in relation to menopausal status, axillary lymph node status, estrogen receptor status, choice and dose of agents, and long-term survival is not defined. Based on experimental background information and theoretical deductions, the clinical results have fallen short of expectations. The data of Bonadonna's CMF study reveal that the overall 5-year survival is increased by 4%; premenopausal patients benefit by 12% whereas treated postmenopausal patients have a 5% less chance of survival. Only those patients benefit who can tolerate a “full or nearly full dose”; these are only 17%. At this time it is not clear whether the small survival differences from adjuvant chemotherapy represent a real step forward in the fight against breast cancer. In the majority of patients (75 to 85%), at the time of adjuvant chemotherapy, systemically disseminated cancer cells are at mitotic rest or their proliferation is minimal. At this stage, adjuvant chemotherapy has no or little effect. Therefore, only a small proportion of patients (15 to 25%) has subclinical systemic cancer growth at the time of primary therapy or thereafter; only these patients have a chance to respond to chemotherapy. In view of this tumor kinetic problem and the hazards of chemotherapy, it seems advantageous (a) to focus on definition of patient subgroups at high risk for early recurrence post primary therapy to serve as participants in trials of adjuvant chemotherapy and/or (b) to concentrate on early diagnosis of recurrent disease for immediate institution of endocrine-and/or polychemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmann DL, Scanlon PW, Bisel HF, Edmonson JH, Frytak S, Payne WS, O'Fallon JR, Hahn RG, Ingle JN, O'Connell MJ, Rubin J (1978) Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. Lancet 1:893–896

    Google Scholar 

  2. Aiginger P (1978) Steroidhormonrezeptoren — Ihre Bedeutung für die Behandlung des Mammakarzinoms. Acta Med Austriaca 5:156–158

    Google Scholar 

  3. Auclerc G, Jacquillat C, Weil M, Auclerc MF, Debonniere C (1979) Analysis of a co-operative study of adjuvant chemotherapy in breast cancer. Cancer Treat Rev 6 (Suppl):97–100

    Google Scholar 

  4. Baum M (1976) The curability of breast cancer. Br Med J 1:439–442

    Google Scholar 

  5. Betzler M, Flad HD, Huget R, Schreml W, Schlag P, Herfarth C (1978) Quantitatives and funktionelles Verhalten lymphatischer Subpopulationen unter einer adjuvanten intermittierenden Chemoimmunotherapy beim Mammacarcinom. Chir Forum Exp Klin Forsch 227–230

  6. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410

    Google Scholar 

  7. Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915

    Google Scholar 

  8. Bonadonna G (1978) Bonadonna's results at four years: still big improvement for CMF group. The Cancer Letter 4 (No. 47):4

    Google Scholar 

  9. Bonadonna G, Valagussa P, Rossi A, Zucali R, Tancini G, Bajetta E, Brambilla C, De Lena M, Di Fronzo G, Banfi A, Rilke F, Veronesi U (1978) Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol 5:450–464

    Google Scholar 

  10. Bonadonna G, Valagussa P, Rossi A, Veronesi U (1978) Improvement of disease-free and overall survival by adjuvant CMF in operable breast cancer. Proc Am Assoc Cancer Res 19:215

    Google Scholar 

  11. Bonadonna G (1980) Breast cancer. Adjuvant chemotherapy of breast cancer. J Appl Med 6 (No. 7):571–574

    Google Scholar 

  12. Bonadonna G, Valagussa P, Tancini G, Di Fronzo G (1980) Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer. Cancer Chemother Pharmacol 4:37–41

    Google Scholar 

  13. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15

    Google Scholar 

  14. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Marchini S, Veronesi U (1982) Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: The Milan Institute Experience. Recent Results Cancer Res 80:149–156

    Google Scholar 

  15. Bond WH (1968) The influence of various treatments on survival rates in cancer of the breast. In: Jarrett AS (ed) The treatment of Carcinoma of the Breast. Syntex Pharmaceuticals Ltd., Maidenhead, pp 24–39

    Google Scholar 

  16. Booth BW, Weiss RB (1981) Venous thrombosis during adjuvant chemotherapy. N Engl J Med 305:170

    Google Scholar 

  17. Bruckman JE, Harris JR, Levene MB, Chaffey JT, Hellman S (1979) Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 43:985–993

    Google Scholar 

  18. Brunner KW, Goldhirsch A, Joss R, Sonntag RW, Tschopp L (1981) Resultate und Indikationen der adjuvanten Chemotherapie beim Mammakarzinom. Schweiz Med Wochenschr 111:838–845

    Google Scholar 

  19. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh Em, Freireich EJ, Gehan EA (1979) Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA 242:1509–1513

    Google Scholar 

  20. Calabresi P, Parks RE Jr (1980) Antiproliferative agents and drugs used for immunosuppression. In: Goodman Gilman A, Goodman LS, Gilman A (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th edn. MacMillan Publishing Co., Inc., New York, pp 1256–1313

    Google Scholar 

  21. Caprini JA, Oviedo MA, Cunningham MP, Cohen E, Trueheart RS, Khandekar JD, Scanlon EF (1980) Adjuvant chemotherapy for stage II and III breast carcinoma. JAMA 244:243–246

    Google Scholar 

  22. Carey RW, Sohier WD, Kaufman S, Weitzman SA, Kelley RM, Lew RA, Halpern E (1979) 5-drug adjuvant chemotherapy for breast cancer. Cancer 44:35–41

    Google Scholar 

  23. Carpenter JT Jr, Maddox WA, Laws HL, Wirtschafter DD, Soong SJ (1982) Favorable factors in the adjuvant therapy of breast cancer. Cancer 50:18–23

    Google Scholar 

  24. Carter SK (1980) Surgery plus adjuvant chemotherapy — a review of therapeutic implications. I Breast cancer. Cancer Chemother Pharmacol 4:147–163

    Google Scholar 

  25. Chabner BA (1977) Second neoplasm — A complication of cancer chemotherapy. N Engl J Med 297:213–214

    Google Scholar 

  26. Chabner BA, Cohen M, Lippman M (1978) Adjuvant therapy of breast cancer: accomplishments and future course. JAMA 239:2373–2374

    Google Scholar 

  27. Chu AM, Kiel K (1982) Comparison of adjuvant postoperative radiotherapy and multiple-drug chemotherapy (CMF-VP) in operable breast cancer patients with more than four positive axillary lymph nodes. Cancer 50:212–218

    Google Scholar 

  28. Cocconi G, De Lisi V, Mori P, Bozzetti C (1982) Estrogen receptors and response to chemotherapy in advanced breast cancer. Tumori 68:67–71

    Google Scholar 

  29. Cohen E, Scanlon EF, Caprini JA, Cunningham MP, Oviedo MA, Robinson B, Knox KL (1982) Follow-up adjuvant chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast. Cancer 49:1754–1761

    Google Scholar 

  30. Cohen RE, Horton J, Ruckdeschel JC, Blanchard CG, Last CG, Dudek BC (1981) Adjuvant chemotherapy said to intensify fears after mastectomy. Ob Gyn News 16 (No. 4):9

    Google Scholar 

  31. Cooke T, George WD, Griffiths K (1980) Possible tests for selection of adjuvant systemic therapy in early cancer of the breast. Br J Surg 67:747–750

    Google Scholar 

  32. Cooper MR, Rhyne AL, Muss HB, Ferree C, Richards F II, White DR, Stuart JJ, Jackson DV, Howard V, Shore A, Spurr CL (1981) A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer 47:2833–2839

    Google Scholar 

  33. Cooper RG, Holland JF, Glidewell O (1979) Adjuvant chemotherapy of breast cancer. Cancer 44:793–798

    Google Scholar 

  34. Corder MP, Jochimsen PR (1982) Marrow neutrophil reserve after adjuvant chemotherapy for carcinoma of the breast. Cancer 49:2455–2458

    Google Scholar 

  35. Crowther D (1979) Controlled adjuvant chemotherapy trials for breast cancer in the United Kingdom. In: Jones SE, Salmon SE (eds) Adjuvant Therapy of Cancer II. Grune & Stratton, New York, pp 237–244

    Google Scholar 

  36. Davis HL, Metter GE, Ramirez G, Grage TB, Cornell G, Fletcher W, Moss S, Multhauf P (1979) An adjuvant trial of l-phenylalanine mustard (L-PAM) vs cyclophosphamide (C), Methotrexate (M) 5-fluorouracil (F) and vincristine (V) — CMF-V following mastectomy for operable breast cancer. Proc Am Assoc Can Res 20:358

    Google Scholar 

  37. De Boever J, De Geest K, Van Maele G, Vandekerckhove D (1981) Estrogen receptors in breast cancer. Excerpta Med Int Congr Ser 515:41–47

    Google Scholar 

  38. Dent DM (1977) Adjuvant chemotherapy for breast cancer. S Afr Med J 52:714–716

    Google Scholar 

  39. Edelstyn GA, MacRae KD (1979) Trials of adjuvant chemotherapy in breast cancer. Lancet 1:324

    Google Scholar 

  40. Executive Committee of the Danish Breast Cancer Cooperative Group (1980) Increased breast-cancer recurrence rate after adjuvant therapy with Levamisole. A preliminary report. Lancet 2:824–827

    Google Scholar 

  41. Faber P, Jesdkinsky H (1979) Adjuvant chemotherapy in breast cancer — a multicenter trial. Cancer Treat Rev 6 (Suppl):75–78

    Google Scholar 

  42. Falkson HC, Falkson G, Portugal MA, Schoeman HS, Louw EM (1982) Adjuvant chemotherapy for operable breast cancer in premenopausal women. S Afr Med J 61:651–655

    Google Scholar 

  43. Firusian N, Hossfeld DK, John V (1978) Adjuvante Chemotherapie des Mamma-Ca. Roentgenblaetter 31:423–428

    Google Scholar 

  44. Fisher B (1969) Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer. Cancer 24:1286–1289

    Google Scholar 

  45. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER (1975) L-phenylalanine mustard (L-Pam) in the management of primary breast cancer. N Engl J Med 292:117–122

    Google Scholar 

  46. Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528–534

    Google Scholar 

  47. Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H (and other cooperating investigators) (1977) L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer 39:2883–2903

    Google Scholar 

  48. Fisher B, Sherman B, Rockette H, Redmond C, Margolese R, Fisher ER (1979) L-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer 44:847–857

    Google Scholar 

  49. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H, and other NSABP investigators (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1–6

    Google Scholar 

  50. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B (1980) Collaborating NSABP investigators: correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45:349–353

    Google Scholar 

  51. Gapinski PV, Donegan WL (1980) Estrogen receptors and breast cancer: prognostic and therapeutic implications. Surgery 88:386–393

    Google Scholar 

  52. Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gadel-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C (1982) Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes. Cancer 50:423–434

    Google Scholar 

  53. Hahn P, Hallberg O, Vikterlöf KJ (1978) Acute skin reactions in postoperative breast cancer patients receiving radiotherapy plus adjuvant chemotherapy. AJR 130:137–139

    Google Scholar 

  54. Hamlin IME (1968) Possible host resistance in carcinoma of the breast: a histological study. Br J Cancer 22:383–401

    Google Scholar 

  55. Harris CC (1979) A delayed complication of cancer therapy — cancer. JNCI 63:275–277

    Google Scholar 

  56. Hartveit F (1980) Axillary node histology in cases of infiltrating breast cancer without nodal metastases dying later of disseminated disease. Invest Cell Pathol 3:311–314

    Google Scholar 

  57. Hartveit F, Støa KF, Tangen M (1981) Implications of oestrogen receptor status in primary breast carcinoma to the role of adjuvant chemotherapy in node-negative cases. Oncology 38:219–221

    Google Scholar 

  58. Hilf R, Feldstein ML, Gibson SL, Savlov ED (1980) The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45:1993–2000

    Google Scholar 

  59. Hill GJ II (1980) Adjuvant chemotherapy — A research tool only? Program for the American College of Surgeons Sixty-Sixth Annual Clinical Congress, Atlanta, Ga., Oct. 19–24, 1980, PGC No. 10/96

  60. Holland JF, Glidewell O, Cooper RG (1980) Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast. Surg Gynecol Obstet 150:817–821

    Google Scholar 

  61. Hubay CA, Pearson OH, Marshall JS, Rhodes RS, Debanne SM, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL (1980) Antiestrogen, cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: A preliminary report. Surgery 87:494–501

    Google Scholar 

  62. Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodes RS, DeBanne SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL (1981) Adjuvant therapy of stage II breast cancer. 48-month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1:77–82

    Google Scholar 

  63. Humphrey LJ (1980) Update of adjuvant therapy for malignant melanoma and carcinoma of the breast: whom do you believe? Amer Surg 46:20–23

    Google Scholar 

  64. Jonat W, Maass H (1981) Hormonrezeptoren im Behandlungsplan des Mammakarzinoms. Arch Geschwulstforsch 51:637–641

    Google Scholar 

  65. Jones SE, Salmon SE, Allen H, Giordano GF, Davis S, Chase E, Moon TE, Heusinkveld RS (1982) Adjuvant treatment of node-positive breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: Interim results of an ongoing clinical trial. Recent Results Cancer Res 80:162–169

    Google Scholar 

  66. Jungi WF, Senn HJ (1978) Prognoseverbesserung durch adjuvante postoperative Chemotherapie des operierten Mammakarzinoms. In: Schmähl D (ed) Behandlung und Nachbehandlung des Mammakarzinoms, vol 2. Georg Thieme Verlag, Stuttgart, pp 155–163

    Google Scholar 

  67. Kardinal CG, Donegan WL (1980) Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast. Cancer 45:2042–2046

    Google Scholar 

  68. Kolata GB (1980) Dilemma in cancer treatment. Science 209:792–794

    Google Scholar 

  69. Kreienberg R, Melchert F, Lemmel EM (1979) Results of monitoring the immune status of patients with breast carcinoma during adjuvant chemotherapy or polychemotherapy. Onkologie 2:181–186

    Google Scholar 

  70. Leake RE, Laing L, McArdle C, Smith DC (1981) Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis. Br J Cancer 43:67–71

    Google Scholar 

  71. Leiberman DP, Berstock DA, Houghton J, Kearney G (1979) Oral adjuvant therapy in breast carcinoma — a multicentre trial. Cancer Treat Rev 6 (Suppl):91–96

    Google Scholar 

  72. Lerner HJ (1978) Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep 62:1135–1138

    Google Scholar 

  73. Lohrmann HP, Schreml W, Lang M, Betzler M, Fliedner TM, Heimpel H (1978) Changes of granulopoiesis during and after adjuvant chemotherapy of breast cancer. Br J Haematol 40:369–381

    Google Scholar 

  74. Meakin JW (1980) Is there a place for adjuvant endocrine therapy of breast cancer? Recent Results Cancer Res 71:178–184

    Google Scholar 

  75. Melchert F, Kreienberg R, von Nathusius U (1980) Adjuvante Chemotherapie beim Mammakarzinom. Fortschr Med 98:281–286

    Google Scholar 

  76. Meyerowitz BE, Sparks FC, Spears IK (1979) Adjuvant chemotherapy for breast carcinoma: psychosocial implications. Cancer 43:1613–1618

    Google Scholar 

  77. Milsted RAV, Fox RM, Tattersall MHN, Woods RL (1980) Cancer chemotherapy — what have we achieved? Lancet 1:1343–1346

    Google Scholar 

  78. Morrison JM (1979) The West Midlands co-operative trial of adjuvant chemotherapy for operable breast cancer. Cancer Treat Rev 6 (Suppl):87–90

    Google Scholar 

  79. Mortimer J, Reimer R, Greenstreet R, Groppe C, Bukowski R (1981) Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer. Cancer Treat Rep 65:763–766

    Google Scholar 

  80. Mueller CB, Ames F (1978) Bilateral carcinoma of the breast: frequency and mortality. Can J Surg 21:459–465

    Google Scholar 

  81. Mueller CB, Ames F, Anderson GD (1978) Breast cancer in 3,558 women: age as a significant determinant in the rate of dying and causes of death. Surgery 83:123–132

    Google Scholar 

  82. Murray JG, MacIntyre J, Leiberman DP, Leaper DJ (1978) Toxicity of oral adjuvant chemotherapy in breast cancer. Br Med J 1:408–409

    Google Scholar 

  83. Muss HB, White DR, Michielutte R, Richards F II, Cooper MR, Williams S, Stuart JJ, Spurr CL (1979) Written informed consent in patients with breast cancer. Cancer 43:7549–7556

    Google Scholar 

  84. NIH Consensus-Development Panel (1980) NIH Consensus-Development Statement. Adjuvant chemotherapy of breast cancer. N Engl J Med 303:831–832

    Google Scholar 

  85. Nissen-Meyer R (1979) One short chemotherapy course in primary breast cancer: 12 year follow-up in series 1 of the Scandinavian adjuvant chemotherapy study group. In: Jones SE, Salmon SE (eds) Adjuvant Therapy of Cancer II. Grune & Stratton, New York, pp 207–213

    Google Scholar 

  86. Nixon DW, Shlaer SM (1981) Fulminant lung metastases from cancer of the breast. Med Ped Oncol 9:381–385

    Google Scholar 

  87. Nowell P, Glick JH, Bucolo A, Finan J, Creech R (1981) Cytogenetic studies of bone marrow in breast cancer patients after adjuvant chemotherapy. Cancer 48:667–673

    Google Scholar 

  88. Oeser H (1980) Das Mammakarzinom, biometrisch betrachtet. Dtsch Med Wochenschr 105:1124–1127

    Google Scholar 

  89. Palmer BV, Walsh GA, McKinna JA, Greening WP (1980) Adjuvant chemotherapy for breast cancer: side effects and quality of life. Br Med J 281:1594–1597

    Google Scholar 

  90. Patil SR, Jochimsen PR, Dick FR, Corder MP (1979) Chromosome abnormalities in the bone marrow of patients after chemotherapy for breast carcinoma. Am J Hum Genet 31 (No. 6):106a

  91. Peek U, Tanneberger St, Heise E, Görlich M, Nissen E, Marx G, Projan A, Winkler R, Kunde D, Bodek B (1981) High risk breast cancer: Long-term surgical adjuvant therapy based on predictive tests — preliminary report. Arch Geschwulstforsch 51:139–151

    Google Scholar 

  92. Portugal MA, Falkson HC, Stevens K, Falkson G (1979) Acute leukemia as a complication of long-term treatment of advanced breast cancer. Cancer Treat Rep 63:177–181

    Google Scholar 

  93. Powles TJ, Smith IE, Ford HT, Coombes RC, Jones JM, Gazet J-C (1980) Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1:580–582

    Google Scholar 

  94. Queißer W (1980) Adjuvante Chemotherapie des Mammakarzinoms. Fortschr Med 98:286–288

    Google Scholar 

  95. Recchione C, Rossi A (1979) Hormonal study in patients developing amenorrhea during adjuvant chemotherapy for breast cancer. Tumori 65:93–97

    Google Scholar 

  96. Rivkin S, Glucksberg H, Rasmussen S (1979) Adjuvant chemotherapy in stage II breast cancer. Proc Am Assoc Cancer Res 20:353

    Google Scholar 

  97. Rose DP, Davis TE (1980) Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 40:4043–4047

    Google Scholar 

  98. Rosner F, Carey RW, Zarrabi MH (1978) Breast cancer and acute leukemia: Report of 24 cases and review of the literature. Am J Hematol 4:151–172

    Google Scholar 

  99. Rossi A, Bonadonna G, Valagussa P, Veronesi U (1977) Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program. Recent Results Cancer Res 62:134–142

    Google Scholar 

  100. Rubens RD, King RJB, Sexton S, Minton MJ, Hayward JL (1980) Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 4:43–45

    Google Scholar 

  101. Russell IS (1977) Adjuvant chemotherapy in the treatment of breast cancer. Aust Fam Physician 6:629–635

    Google Scholar 

  102. Samaan NA, deAsis DN Jr, Buzdar AU, Blumenschein GR (1978) Pitutiary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 44:2084–2087

    Google Scholar 

  103. Schmähl D (1977) Toxikologie in der Krebsforschung. II. Kanzerogene Arzneimittel. Dtsch Med Wochenschr 102:1047–1050

    Google Scholar 

  104. Senn HJ, Mayr AC (1979) Adjuvant chemotherapy in breast cancer — Swiss co-operative studies. Cancer Treat Rev 6 (Suppl):79–85

    Google Scholar 

  105. Senn HJ (1981) Adjuvante Chemotherapie beim Mammakarzinom. Dtsch Med Wochenschr 106:1626–1630

    Google Scholar 

  106. Senn HJ (1982) Current status and indications for adjuvant therapy in breast cancer. Can Chemother Pharmacol 8:139–150

    Google Scholar 

  107. Sherman BM, Wallace RB, Jochimsen PR (1979) Hormonal regulation of the menstrual cycle in women with breast cancer: effect of adjuvant chemotherapy. Clin Endocrinol (Oxf) 10:287–296

    Google Scholar 

  108. Stephens RB, Abeloff MD, Mellits ED, Baker RR (1982) The role of estrogen receptor status in predicting the response of carcinoma of the breast to adjuvant chemotherapy. Surg Gynecol Obstet 154:200–204

    Google Scholar 

  109. Stoll BA (1978) Ovarian function and adjuvant chemotherapy for breast cancer. Lancet 1:1159

    Google Scholar 

  110. Valenta J, Levý J (1977) Combination of regional chemotherapy and mastectomy in the treatment of carcinoma of the breast. Five-year results. Neoplasma 24:415–420

    Google Scholar 

  111. Vaughan WP, Wilcox PM, Alderson PO, Ettinger DS, Abeloff MD (1979) Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breast. Med Pediatr Oncol 7:351–359

    Google Scholar 

  112. Vorherr H (1980) Breast Cancer: Epidemiology, Endocrinology, Biochemistry and Pathobiology. Urban & Schwarzenberg, Baltimore-Munich

  113. Vorherr H (1981) Adjuvant chemotherapy of breast cancer: tumour kinetics and survival. Lancet 2:690

    Google Scholar 

  114. Wendt AG, Mill RC, Heusinkveld RS, Giordano GF, Jackson RA, Salmon SE, Jones SE (1979) Adjuvant treatment of breast cancer with adriamycin-cyclophosphamide +/- radiotherapy. Program and abstracts of the 2nd International Conference on the Adjuvant Therapy of Cancer, March 28–31, 1979, Tucson, AZ University of Arizona Cancer Center (Tucson, AZ), p 56

  115. Weymar P, Jonat W, Langnickel D, Maass H (1980) Erste Ergebnisse verschiedener nach histologischen und biochemischen Kriterien ausgerichteter Behandlungsmethoden nach primär operiertem Mamma-Carcinoma aus den Jahren 1976–1979. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe 43. Tagung, Hamburg 29.9.–3.10.1980, Schmidt-Matthiesen H, Schuhmann R (eds)

  116. Zajicek G (1980) The risk of cancer therapy. Med Hypotheses 6:727–733

    Google Scholar 

  117. Zucali R, Volterrani F, Kenda R, Uslenghi C (1980) Radiotherapy alone and radiotherapy followed by radical mastectomy in T2 breast cancer. Tumori 66:93–100

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Obstetrics-Gynecology and of Pharmacology, The University of New Mexico, School of Medicine, Albuquerque, New Mexico

    H. Vorherr

Authors
  1. H. Vorherr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vorherr, H. Adjuvant chemotherapy of breast cancer: Hope — Reality — Hazard?. Klin Wochenschr 62, 149–161 (1984). https://doi.org/10.1007/BF01731637

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01731637

Key words

Search

Navigation